Dexcom (DXCM) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is DXCM's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

DexCom NASDAQ: DXCM expects a record number of new patients in 2026 and is preparing for a potential expansion of Medicare coverage for continuous glucose monitoring, executives said during a discussion hosted by Jefferi…

DexCom, Inc. (DXCM) Presents at Jefferies Global Healthcare Conference 2026 Transcript…

Aberdeen Group plc cut its holdings in DexCom, Inc. (NASDAQ: DXCM) by 14.8% during a recent quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3…

Commonwealth Equity Services LLC raised its position in DexCom, Inc. (NASDAQ: DXCM) by 18.0% during the third quarter, according to its most recent filing with the SEC. The firm owned 70,241 shares of the medical device …

DexCom's G7 15 Day adoption, international expansion and margin gains support its growth prospects, though competition and rising investments pose challenges.…

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026.The live …

DXCM's upcoming Canadian launch of the G7 15 Day CGM, offering longer sensor wear and improved convenience, could boost international growth and patient access.…

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today launched A Letter to Diabetes in honor of National Diabetes Awareness Month and World Diabetes Day, creating a platf…

DXCM's recurring sensor model synergizes nicely with wider diabetes access thanks to Medicare. In fact, broader Medicare coverage could expand their overall addressable market, as long as DXCM is able to execute on that …

DXCM shares rise as Q3 earnings and revenues beat estimates, margins expand and 2026 guidance improves, driven by strong U.S. demand and G7 15 Day adoption.…

DexCom, Inc. (DXCM) Q3 2026 Earnings Call Transcript…

DexCom NASDAQ: DXCM reported third-quarter 2026 revenue of $1.34 billion, up 11% from a year earlier on both a reported and organic basis, as U.S. growth, market-share gains and manufacturing improvements supported highe…

DexCom (DXCM) came out with quarterly earnings of $0.73 per share, beating the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $0.61 per share a year ago.…

DexCom (NASDAQ:DXCM) reported third-quarter financial results on Thursday. The transcript from the company's third-quarter earnings call has been provided below.…

Diabetes wearables-maker Dexcom topped third-quarter earnings forecasts Thursday and reported in-line sales. Dexcom stock was little moved.…

SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports Third Quarter 2026 Financial Results.…

BURNABY, British Columbia--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today that the Dexcom G7 15 Day Continuous Glucose Monitoring System (CGM) will be available in …

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket p…

DXCM Q3 earnings are likely to benefit from CGM adoption, G7 15 Day uptake and wider reimbursement amid tougher international comparisons.…

On October 21, 2026, DexCom Inc (DXCM) shares fell 6.4% to a current price of $80.26. This decline comes amidst a 52-week range of $54.11 to $92.59, highlightin…

DXCM's G7 delivers strong results in the CONNECT study, improving A1C levels and glucose control in non-insulin users with Type 2 diabetes, supporting CGM adoption.…

DexCom, Inc. (NASDAQ: DXCM - Get Free Report) EVP Michael Brown sold 1,700 shares of the business's stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $85.48, for a total value …

DexCom is transforming into the premium CGM provider with the lowest cost per patient-day and robust clinical evidence, especially for non-insulin Type 2 diabetes. The G7 15-Day sensor transition cut manufacturing costs,…

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced that results from the landmark CONNECT randomized controlled trial have been published in The New England …

SAN DIEGO--(BUSINESS WIRE)--DEXCOM, INC. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the launch of the fifth season of Dexcom U, the company's one-of-a-kind NIL (Name, Image and Likeness) pro…

MILAN--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today released its “Dexcom State of Type 2 Report: Global Access and Attitudes to Diabetes Technology” in advance of the 62nd …

SAN DIEGO--(BUSINESS WIRE)--Dexcom Promotes Jereme Sylvain to Chief Operating Officer.…

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Glenn Boehnlein to its Board of Directors, effective September 10, 2026. Mr. Boehnlein i…
Kept in their own lane. A press release is the company talking, not reporting.
Expected by Feb 8. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

